Disability Index News Today

Switching from biosimilar CT-P13 to SB2 is safe and effective, according to new research. The patients in the study had no significant changes in their psychometric assessments during the 12 month follow up.

A network meta-analysis lends "compelling" support to the practice of switching patients with RA from biologics to less costly biosimilars at 6 months.

A switch from a biologic treatment to a biosimilar demonstrated comparable effects for both primary and co-primary outcomes in patients with rheumatoid arthritis.

August's Condition Watch focuses on skin health.

-- New data illustrate impact of KRYSTEXXA (pegloticase) injection with methotrexate to improve patient outcomes and clinical measures for uncontrolled gout -- Horizon Therapeutics plc (Nasdaq: HZNP)

Post-hoc analysis from DISCOVER-2 show patients who achieve a clinical response by week 8 generally go on to see quality-of-life improvements past 1 year.

Knowledge of the prevalence and socio-demographic characteristics of physical impairments is limited. This study aimed to determine the prevalence of physical impairments among adults in Denmark, both in total and according to nine common diagnostic subgroups, describe the socio-demographic and socio-economic profile, and compare the data with those of the general adult population. This descriptive, cross-sectional, register-based study evaluated the general socio-demographic and socio-economic ...

Women with PsA were more likely to have worse disease burden, pain, fatigue, quality of life, and greater disability and work impairment compared with men.

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with...

An intervention of 24 Pilates sessions achieved reduced pain and improved functional capacity in postoperative patients with breast cancer.